Once-daily RELEXXII® (methylphenidate hydrochloride extended-release tablet) supports Attention Deficit Hyperactivity Disorder (ADHD) Awareness Month

ALPHARETTA, Ga., Oct. 6, 2026 /PRNewswire/ -- October marks ADHD Awareness Month, shining a light on the need for timely diagnosis and personalized treatment. Vertical Pharmaceuticals is dedicated to supporting the ADHD community and the importance of precision dosing.

Approximately 11.7% of U.S. children and adolescents in the United States have been diagnosed with ADHD, while adult diagnoses are estimated to be around 6%.¹ Yet, despite this prevalence, misconceptions remain, especially for women, whose symptoms may be less visible and more easily overlooked. Common symptoms of ADHD include persistent patterns of inattention, hyperactivity, and impulsivity that can affect daily functioning.²

Clinically, ADHD presents uniquely in every individual and finding the right treatment and dose can make all the difference in achieving effective symptom control. Careful dose optimization of methylphenidate has been shown to provide significant symptom management benefits, especially in children, highlighting the need for ongoing medication management. This management is made easier by the availability of multiple tablet strengths.³

"Alora, Vertical Pharmaceuticals' parent company, is driven by a commitment to innovation and patient well-being, and we're proud to stand with the ADHD community by advancing therapies that make a meaningful difference in everyday life. RELEXXII gives providers the flexibility to titrate treatment with precision, supporting the unique needs of individuals impacted by ADHD."-Art Deas, CEO, Alora Pharmaceuticals

If you or a loved one is experiencing ADHD symptoms, we encourage you to have a conversation with your healthcare provider. Together with healthcare providers, who lead diagnosis and treatment, we support precision dosing so that patients can achieve the most effective, individualized care. At Vertical Pharmaceuticals, we are committed to helping the ADHD community thrive.

For further support, explore these trusted ADHD resources for patients and caregivers: ADDitude Magazine, American Academy of Child and Adolescent Psychiatry, American Professional Society of ADHD and Related Disorders, Children and Adults with Attention-Deficit Hyperactivity Disorder, National Institute of Mental Health, and The Attention Deficit Disorder Association.

For more information on RELEXXII^® please visit relexxii.com. For Important Safety Information visit relexxii.com/isi. For full Prescribing Information, including BOXED WARNING, visit relexxii.com/pi. For U.S. residents only.

About Alora Pharmaceuticals, LLC

Headquartered in Alpharetta, GA, Alora Pharmaceuticals is a pharmaceutical company driven by a commitment to quality, reliability, and affordability. Alora Pharmaceuticals is the parent company of seven specialty pharmaceutical and pharmaceutical manufacturing companies with facilities in Texas and Georgia. The Alora family of companies includes Acella Pharmaceuticals, Avion Pharmaceuticals, Neuvosyn Laboratories, Osmotica Pharmaceuticals, Sovereign Pharmaceuticals, Trigen Laboratories, and Vertical Pharmaceuticals. With more than 550 employees, the Alora family of companies is proud to manufacture medicines in the United States, supporting domestic production, supply chain resilience, and patient access to affordable treatments.

Relexxii^® is a registered trademark of Vertical Pharmaceuticals, LLC.

References: 1. https://mhstats.org/blog/how-many-people-have-adhd/ 2. https://www.cdc.gov/adhd/signs-symptoms/ 3. Childress AC, et al. Clin Pharmacol Drug Dev. 2025;0(0):1-7.

SOURCE Alora Pharmaceuticals, LLC